Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

• Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum [ Time Frame: At Year 5 and 6 ] [ Designated as safety issue: No ]
  Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL).
• Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum [ Time Frame: At Years 7, 8, 9, 10 ] [ Designated as safety issue: No ]
• Number of Seroconverted Subjects. [ Time Frame: At Year 5 and Year 6 ] [ Designated as safety issue: No ]
  Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study.
• Number of Seroconverted Subjects. [ Time Frame: At Years 7, 8, 9, 10 ] [ Designated as safety issue: No ]

• Total Immunoglobulin G (IgG) Antibody Titers in Serum [ Time Frame: At Year 5 and Year 6 ] [ Designated as safety issue: No ]
  IgG antibody titers were expressed as GMTs in microgram per milliliter (µg/mL).
• Total Immunoglobulin G (IgG) Antibody Titers in Serum [ Time Frame: At Years 7, 8, 9, 10 ] [ Designated as safety issue: No ]
• Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS) [ Time Frame: At Year 5 and Year 6 ] [ Designated as safety issue: No ]
  Anti-HPV-16/18 titers in CVS were given as GMTs expressed in ELISA units per milliliter (EL.U/mL).
• Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS) [ Time Frame: At Years 7, 8, 9, 10 ] [ Designated as safety issue: No ]
• Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS [ Time Frame: At Year 5 and Year 6 ] [ Designated as safety issue: No ]
  Titers were given as GMTs expressed in microgram per milliliter (µg/mL).
• Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS [ Time Frame: At Years 7, 8, 9, 10 ] [ Designated as safety issue: No ]
• Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication). [ Time Frame: From Month 48 in primary study (NCT00196937) up to Month 60 (Year 5) ] [ Designated as safety issue: No ]
  SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
• Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication). [ Time Frame: From the Month 60 (Year 5) visit until the Month 72 (Year 6) visit ] [ Designated as safety issue: No ]
  SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
• Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication). [ Time Frame: From Month 72 (Year 6) visit to Month 84 (Year 7) visit ] [ Designated as safety issue: No ]
  SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
• Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication). [ Time Frame: Until Year 10 ] [ Designated as safety issue: No ]
• Number of Subjects With Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication). [ Time Frame: From Year 0 up to Year 7 ] [ Designated as safety issue: No ]
  SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

• Evaluation of immune response to components of the vaccine in cervico-vaginal samples (CVS) of subjects who volunteer following first dose of GSK 580299 vaccine [ Time Frame: Years 5, 6, 7, 8, 9 and 10 ] [ Designated as safety issue: No ]
• Evaluation of immune response to components of the vaccine in serum from efficacy studies NCT00689741, NCT00120848, NCT00518336 [ Time Frame: Years 5, 6, 7, 8, 9 and 10 ] [ Designated as safety issue: No ]
• Evaluation of immune response to components of the vaccine in serum elicited after natural infection (NCT00122681) [ Time Frame: Years 5, 6, 7, 8, 9 and 10 ] [ Designated as safety issue: No ]
• Evaluation of immune response in serum from subjects who volunteer following first dose of GSK 580299 vaccine [ Time Frame: Years 5, 6, 7, 8, 9 and 10 ] [ Designated as safety issue: No ]
• Occurrence of vaccine-related SAEs (including SAEs related to study procedures and GSK Biological concomitant medication). [ Time Frame: Throughout the study period ] [ Designated as safety issue: No ]

Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity and safety of the GSK Biologicals' 580299 HPV vaccine up to 10 years after administration of the first dose of HPV vaccine (Month 0) in primary study NCT 00196937. This protocol posting deals with objectives & outcome measures of the extension phase from Year 5 to Year 10. The objectives & outcome measures of the primary phase and extension phase up to year 4 are presented in a separate protocol posting (NCT 00196937).

Subjects were aged 15-55 years at the time of entry into the primary study (NCT00196937). No vaccine will be administered in this extension study.

Results on outcome measures describing analyses on other studies are not reported in this record. Please refer to the records mentioned in the respective outcome measure titles.

• Procedure: Blood sampling
  Blood samples will be collected at Years 5, 6, 7, 8, 9 and 10
• Procedure: Cervico-vaginal secretion (CVS) samples
  CVS will be collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteer for this procedure.

• Experimental: Cervarix 15-25 years group
  Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
  Interventions:

  • Procedure: Blood sampling
  • Procedure: Cervico-vaginal secretion (CVS) samples
• Experimental: Cervarix 26-45 years group
  Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
  Interventions:

  • Procedure: Blood sampling
  • Procedure: Cervico-vaginal secretion (CVS) samples
• Experimental: Cervarix 46-55 years group
  Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
  Interventions:

  • Procedure: Blood sampling
  • Procedure: Cervico-vaginal secretion (CVS) samples

Inclusion Criteria:

• Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
• A female who enrolled in NCT00332475 and received three doses of GSK 580299 vaccine.
• Written informed consent obtained from the subject.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.
• Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs occurring less than three months prior to blood sampling.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• Administration of immunoglobulins and/or any blood products within the three months preceding blood sampling.
• Administration or planned administration of any HPV vaccine, other than the three doses of HPV-16/18 vaccine administered in NCT00332475 study.